These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10907968)

  • 41. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dofetilide. UK 68, UK 68798, Tikosyn, Xelide.
    Drugs R D; 1999 Apr; 1(4):304-11. PubMed ID: 10566050
    [No Abstract]   [Full Text] [Related]  

  • 43. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
    Mykytsey A; Bauman JL; Razminia M; Zheutlin T; Wang T; Saleem M; Leal S; Kehoe RF
    J Cardiovasc Pharmacol Ther; 2007 Mar; 12(1):36-43. PubMed ID: 17495256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J; Xue Y; Eto K; Ni C; Hashimoto K
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation.
    Mazur A; Anderson ME; Bonney S; Roden DM
    J Am Coll Cardiol; 2001 Mar; 37(4):1100-5. PubMed ID: 11263615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
    Bashir Y; Thomsen PE; Kingma JH; Møller M; Wong C; Cobbe SM; Jordaens L; Campbell RW; Rasmussen HS; Camm AJ
    Am J Cardiol; 1995 Nov; 76(14):1040-4. PubMed ID: 7484858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potentially significant drug interactions of class III antiarrhythmic drugs.
    Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
    Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
    Coleman CI; Sood N; Chawla D; Talati R; Ghatak A; Kluger J;
    Europace; 2009 Jul; 11(7):892-5. PubMed ID: 19351630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
    Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
    LaPointe NM; Pamer CA; Kramer JM
    Pharmacotherapy; 2003 Oct; 23(10):1316-21. PubMed ID: 14594348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
    Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
    [No Abstract]   [Full Text] [Related]  

  • 52. Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
    Ting C; Malloy R; Knowles D
    J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):438-443. PubMed ID: 32347108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.
    Barrett TD; Hennan JK; Fischbach PS; O'Neill BP; Driscoll EM; Lucchesi BR
    Br J Pharmacol; 2001 Apr; 132(7):1493-500. PubMed ID: 11264243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discontinuation of Dofetilide From QT Prolongation and Ventricular Tachycardia in the Real World.
    Anand V; Vakil K; Tholakanahalli V; Li JM; McFalls E; Adabag S
    JACC Clin Electrophysiol; 2016 Dec; 2(7):777-781. PubMed ID: 29759759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute conversion of persistent atrial fibrillation during dofetilide initiation.
    Cotiga D; Arshad A; Aziz E; Joshi S; Koneru JN; Steinberg JS
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1527-30. PubMed ID: 18070309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
    Nagra BS; Ledley GS; Kantharia BK
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):191-5. PubMed ID: 16211208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pure class III antiarrhythmic drugs: focus on dofetilide.
    Doshi SK; Singh BN
    J Cardiovasc Pharmacol Ther; 2000 Oct; 5(4):237-47. PubMed ID: 11150393
    [No Abstract]   [Full Text] [Related]  

  • 60. Initiation and monitoring of class III antiarrhythmic agents.
    Freeland S; Worthy C; Zolnierz M
    J Cardiovasc Electrophysiol; 2003 Dec; 14(12 Suppl):S291-5. PubMed ID: 15005217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.